Literature DB >> 8568822

Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.

R A Glennon1, S S Hong, M Bondarev, H Law, M Dukat, S Rakhi, P Power, E Fan, D Kinneau, R Kamboj, M Teitler, K Herrick-Davis, C Smith.   

Abstract

In humans, 5-HT1D serotonin receptors represent terminal autoreceptors, and there is some evidence that 5-HT1D ligands may be useful in the treatment of migraine. The most widely used 5-HT1D agonist is sumatriptan; however, this agent reportedly displays little selectivity for 5-HT1D versus 5-HT1A receptors. To identify novel serotonergic agents with enhanced 5-HT1D versus 5-HT1A selectivity, we attempted to take advantage of possible differences in the regions of bulk tolerance associated with the 5-position of the 5-HT binding sites for these two populations of receptors. Examination of a series of 5-(alkyloxy)tryptamine derivatives demonstrated that compounds with unbranched alkyl groups of up to eight carbon atoms bind with high affinity at human 5-HT1D beta receptors (Ki < 5 nM) but demonstrate less than 50-fold selectivity relative to 5-HT1A receptors. Alkyl groups longer than eight carbon atoms impart reduced affinity for 5-HT1A receptors whereas groups longer than nine carbon atoms lead to compounds with reduced affinity at 5-HT1D beta receptors. 5-(Nonyloxy)tryptamine (10) represents a compound with optimal 5-HT1D beta affinity (Ki = 1 nM) and selectivity (> 300-fold). Branching of the alkyl chain, to 5-[(7,7-dimethylheptyl)oxy]tryptamine (15), results in an agent with somewhat lower affinity (5-HT1D beta Ki = 2.3 nM) but with greater (i.e, 400-fold) 5-HT1D versus 5-HT1A selectivity. Replacement of the oxygen atom of 10 with a methylene group (i.e., 20), replacement of the O-proximate methylene with a carbonyl group (i.e., ester 26), or cyclization of the aminoethyl moiety to a carbazole (e.g., 34, 36) or beta-carboline (i.e., 37), result in reduced affinity and/or selectivity. None of the compounds examined displayed significant selectivity for 5-HT1D beta versus 5-HT1D alpha sites; nevertheless, compounds 10 (recently shown to have as a 5-HT1D agonist) and 15 represent the most 5-HT1D versus 5-HT1A selective agents reported to date.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568822     DOI: 10.1021/jm950498t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Serotonin Receptor Agonist 5-Nonyloxytryptamine Alters the Kinetics of Reovirus Cell Entry.

Authors:  Bernardo A Mainou; Alison W Ashbrook; Everett Clinton Smith; Daniel C Dorset; Mark R Denison; Terence S Dermody
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

2.  5-Alkyloxytryptamines are membrane-targeting, broad-spectrum antibiotics.

Authors:  Katherine C Faulkner; Katherine A Hurley; Douglas B Weibel
Journal:  Bioorg Med Chem Lett       Date:  2016-10-05       Impact factor: 2.823

3.  Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth.

Authors:  Jiney Jose; Clint D J Tavares; Nancy D Ebelt; Alessia Lodi; Ramakrishna Edupuganti; Xuemei Xie; Ashwini K Devkota; Tamer S Kaoud; Carla L Van Den Berg; Eric V Anslyn; Stefano Tiziani; Chandra Bartholomeusz; Kevin N Dalby
Journal:  ACS Med Chem Lett       Date:  2017-09-14       Impact factor: 4.345

4.  Neurotransmitter-Responsive Nanosensors for T2-Weighted Magnetic Resonance Imaging.

Authors:  Vivian Hsieh; Satoshi Okada; He Wei; Isabel García-Álvarez; Ali Barandov; Santiago Recuenco Alvarado; Robert Ohlendorf; Jingxuan Fan; Athena Ortega; Alan Jasanoff
Journal:  J Am Chem Soc       Date:  2019-09-30       Impact factor: 15.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.